Labcorp Unveils 10-Minute FDA‑Cleared Fentanyl Test For Emergency Settings
New rapid test for fentanyl exposure
Labcorp (NYSE: LH) has launched the Labcorp Fentanyl Urine Visual Test, billed as the first FDA‑cleared rapid fentanyl test of its kind manufactured in the U.S. The point‑of‑care assay delivers results in about 10 minutes, giving emergency departments, hospitals and clinics fast, preliminary answers when fentanyl exposure is suspected.
How the test works
The test detects norfentanyl, fentanyl’s primary metabolite, which can remain in urine for up to 48 hours—offering a longer detection window than fentanyl itself, which may clear within hours. It is cleared for use in CLIA‑certified settings by trained professionals, with non‑negative results intended to be confirmed by laboratory methods such as mass spectrometry in line with standard rapid‑screening protocols.
Integration with Labcorp Point of Care
The test is available through Labcorp Point of Care, the company’s rebranded MEDTOX Diagnostics unit that provides rapid diagnostic solutions to hospitals and clinics. Throughout 2026, MEDTOX products, packaging and resources will transition to the Labcorp Point of Care branding as the company expands its acute‑care and toxicology footprint.
Investor perspective
For investors, the launch underscores Labcorp’s push deeper into high‑need toxicology and emergency‑department workflows where time‑sensitive decisions are critical. It also complements the company’s lab‑based fentanyl and synthetic opioid testing portfolio, potentially driving incremental demand for confirmatory testing and strengthening Labcorp’s position across the opioid‑diagnostics ecosystem.
